The Vaccine Group (TVG) CEO Dr Jeremy Salt discusses the highly encouraging efficacy results for the company’s Streptococcus suis vaccine candidate, marking an important step forward for its veterinary vaccine platform.
Salt explained that the latest results demonstrate how effective the vaccine candidate can be against Streptococcus suis, a serious bacterial disease affecting pigs globally. He said the findings are particularly significant as they show the strength and flexibility of the company’s platform technology across multiple disease types. “It’s a very nice indication of how effective this vaccine candidate can be against this particular disease,” Salt noted
Streptococcus suis is widely distributed in commercially farmed pigs, with hundreds of millions of animals potentially affected worldwide. Salt highlighted that the disease is a major contributor to antibiotic use in pig farming and that a successful vaccine could help significantly reduce reliance on antibiotics. He also pointed out the zoonotic nature of the disease, which can infect humans who work with pigs or handle pork products, sometimes with severe or fatal outcomes.
TVG has already demonstrated the efficacy of its platform against viral disease, including bovine respiratory syncytial virus in cattle, and Salt said the latest pig data further underlines the breadth of the technology. The company is currently engaged in discussions with a commercial partner and aims to move the Streptococcus suis vaccine into a full development phase.
Salt added that TVG is also seeking partners for its cattle vaccine and intends to use future funding to advance a broader portfolio spanning livestock and companion animals.